|
MorphoSys Chief Says MOR103 Drug Data Makes Deal More Likely
MorphoSys has better chances of finding a partner for its experimental arthritis drug after favorable results from a clinical trial, CEO Simon Moroney said. The compound, named MOR103, would be the first proprietary compound for the Martinsried, Germany-based biotech company, which develops biological drugs for companies such as Roche Holding AG and Novartis AG.
Bloomberg |
Register Now
Archives